An Era Ends: CureVac Completes Merger and Delisting Process

The merger process reached its formal conclusion on January 6, 2026, with Mainz-based BioNTech SE becoming the sole owner. The operational entity, CureVac Merger B.V., has replaced the original ...
Hosted on MSN

CureVac completes BioNTech-driven reorganization and moves to delist from Nasdaq

CureVac ( (CVAC)) just unveiled an update. On January 6, 2026, CureVac N.V. completed a post-offer reorganization tied to BioNTech SE’s exchange offer, resulting in BioNTech becoming the sole owner of ...

CureVac Shareholders Face Final Tax Reclaim Deadline

Investors received 0.05363 BioNTech American Depositary Shares (ADS) for each CureVac share they held. This conversion was applied automatically, even to minority shareholders who did not actively ...
Morningstar

CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2025 and Provides Business Updates

German Federal Cartel Office clearance obtained for the planned BioNTech - CureVac transaction announced on June 12, 2025, marking an important step toward the expected closing later this year Offer ...
Nasdaq

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

MAINZ, Germany, December 3, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that 184,071,410 shares of CureVac N.V. (Nasdaq: CVAC, “CureVac”), representing approximately 81.74% of ...
Seeking Alpha

BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration

Offer set to expire at 9:00 am Eastern Time on December 3, 2025, with CureVac shareholders advised to tender their shares by 6:00 pm Eastern Time on December 2, 2025, due to operational deadlines.
Seeking Alpha

BioNTech Achieves Minimum Condition in CureVac Exchange Offer

The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac’s issued and outstanding shares, tendered prior to the ...